Claristep filtration system: fast, easy and reliable sample preparation
![](/46/pdcnewsitem/04/16/40/img_claristep-detail.jpg)
Easy, reliable and convenient to use: the new Claristep filtration system enables fast clarification of small sample volumes for subsequent analysis.
Fast small-volume clarification that does not add leachables or extractables to the original sample.
Preparing samples by clarification is an essential step prior to nearly all analytical techniques, such as high pressure liquid chromatography (HPLC). This filtration step to eliminate particles is crucial for maintaining the integrity of chromatography columns and for maximizing their operating life time. In addition, as the sensitivity of automated analytical instruments continues to improve, they increasingly require less volume to operate to maximize throughput.
Fast small-volume clarification that does not add leachables or extractables to the original sample is indispensable for achieving the best analytical results. To meet these requirements, Sartorius has developed a new, easy-to-use and straightforward filtration setup. The manually operated Claristep filtration system consisting of a station and filter units offers a novel way for clarifying samples prior to analysis.
The Claristep station consists of a base, a lid and an exchangeable tray for easy and accurate positioning of sample vials and Claristep filter units. The patent-pending design features unique grooves in the station’s lid and matching guide ridges on Claristep filter units to enable intuitively correct alignment and convenient handling of the system. The grooves automatically guide the filter unit caps into the correct positions for simultaneous and accurate cap closure.
Claristep enables up to eight samples to be simultaneously filtered, without needing any power supply or a vacuum/pressure source. Single-use Claristep filter units with RC membranes are designed for sample volumes of 60 μL to 600 μL. Their hold-up volume is less than 30 μL. The units have been optimized for solvents and aqueous solutions and provide maximum chemical compatibility as well as exceptionally low non-specific binding of analytes.
The contact time of the samples with the filters and the caps is extremely short, ensuring optimal, contamination-free results. Filtrates are collected in any 12 × 32 mm outer diameter vials of the user’s choice based on the analytical method to be performed.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance